首页> 外文期刊>American Journal of Cancer Prevention >Percutaneous Radiofrequency Ablation versus Surgical Resection for the Treatment of Small Hepatic Carcinoma: A Meta-analysis
【24h】

Percutaneous Radiofrequency Ablation versus Surgical Resection for the Treatment of Small Hepatic Carcinoma: A Meta-analysis

机译:经皮射频消融与手术切除术治疗小肝癌的Meta分析

获取原文
       

摘要

Aims: To evaluate the curative effect of percutaneous radiofrequency ablation (PRFA) versus surgical resection (SR) for the treatment of small hepatic carcinoma. Methods: Cochrane Library, Medline, Pubmed, CNKI, WanFang, VIP databases were searched from January 1990 to March 2013, then clinical control studies comparing curative effects of PRFA with SR in treatment of small hepatic carcinoma were acquired and reviewed. Qualities of these studies were evaluated. Publication bias was also assessed by using a funnel plot. Then primary outcomes, namely overall survival rates, disease-free survival rates and postoperative complication, were abstracted to conduct a combined analysis by using fixed or random effects model. Results: A total of eight studies involving 1287 patients were included in our study. The PRFA group has a lower overall survival rates over the SR group in 1 year (OR, 0.62; 95% confidence interval [CI], 0.43-0.89; P = 0.009), 3 years (OR, 0.44; 95% CI, 0.27-0.72; P=0.001), and 5 years (OR, 0.49; 95% CI, 0.35-0.68; P<0.0001). The PRFA group has a lower disease-free survival rates over the SR group in 1 year (OR, 0.63; 95% CI, 0.49-0.82; P=0.0006), 3 years (OR, 0.45; 95% CI, 0.30-0.67; P=0.0001), and 5 years (OR, 0.46; 95% CI, 0.33-0.64; P<0.00001). The postoperative complication of the PRFA group was lower than the SR group (OR, 0.21; 95% CI, 0.08-0.56; P<0.00001). Conclusion: PRFA had lower overall survival rates after surgery and disease-free survival than SR, but it has a lower incidence of postoperative complications. Then PRFA, acted as an operation with smaller invasion and shorter hospitalization time, would be a good choice for the patients with hepatic carcinoma who is reluctant to be treated by SR.
机译:目的:评估经皮射频消融(PRFA)与手术切除(SR)治疗小肝癌的疗效。方法:检索1990年1月至2013年3月在Cochrane图书馆,Medline,Pubmed,CNKI,万芳,VIP数据库中的临床资料,比较PRFA和SR治疗小肝癌的疗效。评估了这些研究的质量。还使用漏斗图评估出版偏倚。然后提取主要结果,即总生存率,无病生存率和术后并发症,以固定或随机效应模型进行联合分析。结果:总共八项研究涉及1287名患者,被纳入我们的研究。 PRFA组的总生存率低于SR组的1年(OR,0.62; 95%置信区间[CI],0.43-0.89; P = 0.009),3年(OR,0.44; 95%CI,0.27) -0.72; P = 0.001)和5年(OR,0.49; 95%CI,0.35-0.68; P <0.0001)。 PRFA组的无病生存率比SR组低,一年(OR,0.63; 95%CI,0.49-0.82; P = 0.0006),3年(OR,0.45; 95%CI,0.30-0.67) ; P = 0.0001)和5年(OR,0.46; 95%CI,0.33-0.64; P <0.00001)。 PRFA组的术后并发症低于SR组(OR,0.21; 95%CI,0.08-0.56; P <0.00001)。结论:PRFA术后总生存率和无病生存率均低于SR,但术后并发症发生率较低。然后,对于不愿接受SR治疗的肝癌患者,PRFA手术具有较小的侵袭和较短的住院时间,将是一个不错的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号